75 related articles for article (PubMed ID: 20671857)
1. Major Depressive Disorder Complicated with Spinocerebellar Ataxia: Report of 2 Cases.
Okamoto N; Ogawa M; Murata Y; Sakamoto K; Nagai T; Yamada M; Higuchi T
Case Rep Neurol; 2010 May; 2(2):52-56. PubMed ID: 20671857
[TBL] [Abstract][Full Text] [Related]
2. The role of selective serotonin reuptake inhibitors in preventing relapse of major depressive disorder.
Clevenger SS; Malhotra D; Dang J; Vanle B; IsHak WW
Ther Adv Psychopharmacol; 2018 Jan; 8(1):49-58. PubMed ID: 29344343
[TBL] [Abstract][Full Text] [Related]
3. Neuropsychological features of patients with spinocerebellar ataxia (SCA) types 1, 2, 3, and 6.
Klinke I; Minnerop M; Schmitz-Hübsch T; Hendriks M; Klockgether T; Wüllner U; Helmstaedter C
Cerebellum; 2010 Sep; 9(3):433-42. PubMed ID: 20502998
[TBL] [Abstract][Full Text] [Related]
4. Depression comorbidity in spinocerebellar ataxia.
Schmitz-Hübsch T; Coudert M; Tezenas du Montcel S; Giunti P; Labrum R; Dürr A; Ribai P; Charles P; Linnemann C; Schöls L; Rakowicz M; Rola R; Zdzienicka E; Fancellu R; Mariotti C; Baliko L; Melegh B; Filla A; Salvatore E; van de Warrenburg BP; Szymanski S; Infante J; Timmann D; Boesch S; Depondt C; Kang JS; Schulz JB; Klopstock T; Lossnitzer N; Löwe B; Frick C; Rottländer D; Schlaepfer TE; Klockgether T
Mov Disord; 2011 Apr; 26(5):870-6. PubMed ID: 21437988
[TBL] [Abstract][Full Text] [Related]
5. Analysis of treatment patterns and persistence on branded and generic medications in major depressive disorder using retrospective claims data.
Solem CT; Shelbaya A; Wan Y; Deshpande CG; Alvir J; Pappadopulos E
Neuropsychiatr Dis Treat; 2016; 12():2755-2764. PubMed ID: 27822048
[TBL] [Abstract][Full Text] [Related]
6. Frequency of Spinocerebellar Ataxia type 1, 2, 3,6 and 7 and clinical profile of Spinocerebellar Ataxia type 3 in Malaysia.
Mohamed Ibrahim N; Lau YH; Ariffin N; Md Desa SH; Azizan E; Chin LK; Md Rani SA; Yakob Y; Datuk Puvanarajah S; van de Warrenburg B
Cerebellum Ataxias; 2020; 7():11. PubMed ID: 32922823
[TBL] [Abstract][Full Text] [Related]
7. [Exploration of preventive drugs for spinocerebellar ataxia using cultured cerebellar Purkinje cells].
Seki T
Nihon Yakurigaku Zasshi; 2019; 154(6):310-314. PubMed ID: 31787682
[TBL] [Abstract][Full Text] [Related]
8. Depression and clinical progression in spinocerebellar ataxias.
Lo RY; Figueroa KP; Pulst SM; Perlman S; Wilmot G; Gomez C; Schmahmann J; Paulson H; Shakkottai VG; Ying S; Zesiewicz T; Bushara K; Geschwind M; Xia G; Yu JT; Lee LE; Ashizawa T; Subramony SH; Kuo SH
Parkinsonism Relat Disord; 2016 Jan; 22():87-92. PubMed ID: 26644294
[TBL] [Abstract][Full Text] [Related]
9. [A familial case of spinocerebellar ataxia type 8 (SCA 8)--its clinical findings and an issue about the genetic basis].
Hokezu Y; Takiyama Y; Sakoe K; Nagamatsu K
Rinsho Shinkeigaku; 2000 Nov; 40(11):1116-21. PubMed ID: 11332193
[TBL] [Abstract][Full Text] [Related]
10. Clinical profile and genetic correlation of patients with spinocerebellar ataxia: A study from a tertiary care centre in Eastern India.
Pulai D; Guin DS; Bhattacharyya KB; Ganguly G; Joardar A; Roy S; Biswas A; Pandit A; Roy A; Senapati AK
Ann Indian Acad Neurol; 2014 Oct; 17(4):387-91. PubMed ID: 25506158
[TBL] [Abstract][Full Text] [Related]
11. Increased protein kinase C gamma activity induces Purkinje cell pathology in a mouse model of spinocerebellar ataxia 14.
Ji J; Hassler ML; Shimobayashi E; Paka N; Streit R; Kapfhammer JP
Neurobiol Dis; 2014 Oct; 70():1-11. PubMed ID: 24937631
[TBL] [Abstract][Full Text] [Related]
12. Alteration of transthyretin and thyroxine-binding globulin in major depressive disorder: multiple reaction monitoring-based proteomic analysis.
Woo HI; Park J; Lim SW; Kim DK; Lee SY
J Transl Med; 2021 Jan; 19(1):34. PubMed ID: 33451315
[TBL] [Abstract][Full Text] [Related]
13. Current treatment options: relief of symptoms and ultimate recovery.
Kennedy SH
Int J Psychiatry Clin Pract; 2006; 10 Suppl 1():22-6. PubMed ID: 24931540
[TBL] [Abstract][Full Text] [Related]
14. The Wistar-Kyoto rat model of endogenous depression: A tool for exploring treatment resistance with an urgent need to focus on sex differences.
Millard SJ; Weston-Green K; Newell KA
Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jul; 101():109908. PubMed ID: 32145362
[TBL] [Abstract][Full Text] [Related]
15. Apathy symptoms induced by low-dose venlafaxine: Two cases.
Sato S; Sodeyama N; Matsuzaki A; Shiratori Y
Neuropsychopharmacol Rep; 2020 Jun; 40(2):196-197. PubMed ID: 32267090
[TBL] [Abstract][Full Text] [Related]
16. Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials.
Iovieno N; Tedeschini E; Bentley KH; Evins AE; Papakostas GI
J Clin Psychiatry; 2011 Aug; 72(8):1144-51. PubMed ID: 21536001
[TBL] [Abstract][Full Text] [Related]
17. An observational study of duloxetine versus SSRI monotherapy in Japanese patients with major depressive disorder: subgroup analyses of treatment effectiveness for pain, depressive symptoms, and quality of life.
Kuga A; Tsuji T; Hayashi S; Fujikoshi S; Tokuoka H; Yoshikawa A; Escobar R; Tanaka K; Azekawa T
Neuropsychiatr Dis Treat; 2017; 13():2115-2124. PubMed ID: 28831260
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
